share_log

EFFECT: Others

SEC ·  Apr 22 18:06
Summary by Futu AI
Adial Pharmaceuticals, Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of April 19, 2024, at 5:00 PM. This form is a registration statement that allows companies to issue various securities to the public. The effectiveness of this form indicates that Adial Pharmaceuticals has met all the necessary regulatory requirements to proceed with the issuance of securities.
Adial Pharmaceuticals, Inc. has achieved a significant milestone with the United States Securities and Exchange Commission (SEC) declaring its Form S-3 effective as of April 19, 2024, at 5:00 PM. This form is a registration statement that allows companies to issue various securities to the public. The effectiveness of this form indicates that Adial Pharmaceuticals has met all the necessary regulatory requirements to proceed with the issuance of securities.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.